Adaptive Stereostatic Body RadioTherapy (SBRT) including both Whole Pelvic RadioTherapy (WPRT) and dose-escalation on the Dominant Intraprostatic Lesion (DIL)conventional or a moderately hypofractionated
Adaptive Stereostatic Body RadioTherapy (SBRT) including both Whole Pelvic RadioTherapy (WPRT) and dose-escalation on the Dominant Intraprostatic Lesion (DIL): The doses delivered will be:
* the prostate gland, at a dose of 36.25 Gray, in 5 fractions,
* the dominant intraprostatic lesion, up to 50 Gray, in 5 fractions,
* seminal vesicles, at a dose of 25 Gray in 5 fractions,
* pelvic lymph nodes, at 25 Gray in 5 fractions
conventional or a moderately hypofractionated: * Conventional fractionation includes the prescription of a total dose of 78 Gray in 39 fractions to the prostate gland (and seminal vesicles, in case of T3b disease), and a dose de 50Gy in 25 fractions to pelvic nodal areas.
* Moderate hypofractionation includes the prescription of a total dose of 60 Gray to the prostate gland (and seminal vesicles, in case of T3b disease), and 44 Gray to pelvic nodal areas in 20 fractions using a simultaneous integrated boost (SIB)
Study summary
The aim of this clinical trial is to evaluate the efficacy of adaptive prostate Stereotatic Body RadioTherapy (SBRT), which integrates both Whole Pelvic RadioTherapy (WPRT) and dose escalation on the Dominant Intraprostatic Lesion (DIL), compared with standard radiotherapy. This will be assessed using a 5-year cost-utility analysis based on data from the clinical trial and the National Health Data System (NHDS).
Eligibility
Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Male.
* Age ≥ 18 years
* ECOG (Eastern Cooperative Oncology Group) performance status 0-2
* Histologically proven prostate adenocarcinoma, not previously treated
* High-risk or very high-risk according to the National Comprehensive Cancer Network (NCCN) :
* T3a / T3b (proximal extension only),
* and/or ISUP (International Society of Urological Pathology) grade 4-5,
* and/or PSA (Prostate-Specific Antigen) 20ng/mL
* Non-metastatic, as proven by Prostate Specific Membrane Antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and pelvic MRI (Magnetic Resonance Imaging) less than 2 months before starting hormone therapy
* Normal testosterone levels prior to hormone therapy
* Ability to give consent for inclusion in the study
* Acceptance of treatment and monitoring modalities
Exclusion Criteria:
* Presence of nodal or distant metastases
* Stage T4.
* Prostate volume \> 80 cm3.
* IPSS \>19/35.
* Previous local treatment of prostate adenocarcinoma (HIFU (High-Intensity Focused Ultrasound), cryotherapy)
* Previous TransUrethral Resection of the prostate (PTUR)).
* Previous pelvic radiotherapy.
* Chronic inflammatory bowel disease.
* Active cardiovascular comorbidities (e.g. myocardial infarction or ischemic stroke within the last 6 months).
Primary outcome measure(s)
Efficacy of adaptive prostate Stereostatic Body RadioTherapy (SBRT) integrating both Whole Pelvic RadioTherapy (WPRT) and dose-escalation on the Dominant Intraprostatic Lesion (DIL) — Five years after radiotherapy The primary endpoint is incremental cost effectiveness ratio (ICER) expressed as the cost for each healthy life-year gained at 5 years, with costs estimated from the National Health Data System (NHDS), overall survival (defined as the time between the 1st day of treatment and death from any cause), and utility estimated from clinical trial data
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
